PRL and prostate carcinoma: PRL (endocrine or autocrine), acting via the PRLRLF in vivo, activates the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 (Jak 2-Stat5a/b) pathway, preventing apoptosis and allowing the survival of prostate cancer cells [7].